Clinical trials: Melanoma, Stage II
Melanoma, Lung Cancer
Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
This is a 2-part prospective trial examining the ability of Stereotactic Body Radiation Therapy (SBRT) to induce a response to MK-3475, a humanized antibody to PD-1, in patients who progress on this antibody.
- Trial name
- NCT02407171
- Testing
- MK-3475, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Yale University
Stage IV Melanoma
A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma
This study evaluates the effectiveness of adding a single four-day treatment of the fusion protein A-dmDT390-bisFv(UCHT1) - plus single palliative tumor radiation - with standard of care KEYTRUDA (Pembrolizumab) therapy for the…
- Trial name
- NCT02990416
- Testing
- A-dmDT390-bisFv(UCHT1), Pembrolizumab, Ionizing Radiation
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Virogen Biotechnology Inc.
Melanoma, Cancer
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Primary objective: To evaluate the clinical activity of the vaccine regimen, as indicated by progression-free survival versus the clinical activity of the reference treatment.
- Trial name
- NCT00613509
- Testing
- ALVAC(2) Melanoma multi-antigen therapeutic vaccine, Intron A, Interferon alpha -2b
- Where
- 19 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Melanoma Stage III, Melanoma Stage IV
A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma
The purpose of this study is to determine if TBI-1401(HF10) in combination with ipilimumab is effective in Japanese patients with stages IIIB, IIIC, or IV unresectable or metastatic melanoma.
- Trial name
- NCT03153085
- Testing
- TBI-1401(HF10), Ipilimumab
- Where
- 12 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Takara Bio Inc.
Melanoma, Melanoma (Skin)
Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients
In the BRIM-3 trial, which was conducted in patients with previously untreated advanced melanoma harboring the BRAF V600E mutation, vemurafenib, a potent inhibitor of mutated BRAF, was associated with prolonged overall survival…
- Conditions
- Melanoma, Melanoma (Skin), Melanoma Stage
- Trial name
- VECODUE (NCT03224208)
- Testing
- Vemurafenib, Cobimetinib
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- Fondazione Melanoma Onlus
Breast Cancer, Endometrial Cancer
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
RATIONALE: BI 2536 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well BI 2536 works in treating patients with…
- Conditions
- Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Melanoma (Skin)
- Trial name
- NCT00526149
- Testing
- BI 2536, high performance liquid chromatography, mass spectrometry
- Where
- Belgium
- Volunteers
- 76 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Melanoma (Skin)
Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have stage II, stage III, or stage IV melanoma.
- Trial name
- NCT00010309
- Testing
- MART-1 antigen, gp100 antigen
- Where
- 3 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
Metastatic Melanoma
A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
The purpose of this study is to test the combination of Ipilimumab and GM-CSF. Both ipilimumab and GM-CSF are intended to work with the body's own immune system to attack melanoma cells in the body.
- Trial name
- NCT02009397
- Testing
- Ipilimumab, GM-CSF
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Louisville
Melanoma
A Study of IBI363 in Subjects With Advanced Melanoma
This is an open-lable, multicenter Phase II study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced melanoma patients
- Trial name
- NCT06081920
- Testing
- IBI363
- Where
- 12 sites in China
- Volunteers
- 180 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Melanoma (Skin)
Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to kill tumor cells. Biological therapies such as interferon gamma and interleukin-2 use different ways to stimulate the immune system and…
- Trial name
- NCT00006113
- Testing
- MART-1 antigen, aldesleukin, gp100 antigen
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Southern California
Melanoma
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
The main purpose of this study is to evaluate the safety of Vemurafenib in combination with Metformin in melanoma patients. The phase II part of the study will also evaluate the clinical activity of the combined regiment.
- Trial name
- NCT01638676
- Testing
- Vemurafenib, Metformin
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Louisville
Neoplasms
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous…
- Trial name
- NCT03693612
- Testing
- feladilimab, Tremelimumab, Docetaxel
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
Stage II Cutaneous Melanoma
COmparison of the Use of a PERforator Flap Versus Total Skin GRAft in the Management of Loss of Substance After Resection of Cutaneous Melanoma - Pilot Study
Melanoma is an aggressive and potentially fatal skin cancer and was the fifth most commonly diagnosed cancer among both men and women in the United States in 2022.
- Trial name
- COPERGRAM1 (NCT07354152)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Nantes University Hospital
Cutaneous Melanoma, Melanoma
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
This phase II trial studies the effect of a vaccine called CDX-1401 given with or without a biologic drug called CDX-301 in treating patients with stage IIB-IV melanoma.
- Conditions
- Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary, Mucosal Melanoma
- Trial name
- NCT02129075
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Recombinant Flt3 Ligand
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Melanoma, Metastatic Melanoma
Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma
This is a multi-center, open-label, phase 2 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with locally advanced or metastatic melanoma who have failed in routine systemic treatment.
- Trial name
- NCT03013101
- Testing
- humanized anti-PD-1 monoclonal antibody toripalimab
- Where
- 6 sites in China
- Volunteers
- 128 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Patients at Risk for Melanoma
Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo
This is a phase II intervention to propose a new melanoma chemoprevention agent. The investigators believe oxidative stress/damage in nevi is a probable indication for melanoma risk, and propose that reduced melanoma risk in…
- Trial name
- NCT01612221
- Testing
- N-acetylcysteine
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Utah
Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
This phase II trial tests the safety of positron emission tomography (PET) guided stereotactic body radiation therapy (SBRT) and how well it works to treat non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma…
- Conditions
- Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm, Melanoma, Renal Cell Carcinoma
- Trial name
- NCT05830058
- Testing
- Biospecimen Collection, Computed Tomography, Positron Emission Tomography
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- City of Hope Medical Center
Melanoma (Skin)
ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy, such as ABI-007, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00081042
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Melanoma
Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma
This is an open-labelled single arm trial of pembrolizumab and imatinib mesylate in subjects with unresectable or metastatic KIT-mutant melanoma that are refractory to standard therapy.
- Trial name
- NCT04546074
- Testing
- Pembrolizumab and Imatinib mesylate
- Where
- Japan
- Volunteers
- 22 people
- Sponsor
- Keio University
Melanoma Metastatic
Interleukin-2 in Metastatic Melanoma
To determine whether Interleukin-2 at the dose and schedule will help to increase tumor shrinkage
- Trial name
- NCT01702896
- Testing
- Interleukin-2
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Western Regional Medical Center